Toclizumab For Rheumatoid Arthritis - Video

Toclizumab is a humanized anti-interleukin 6 receptor agent that blocks the action of the inflammatory cytokine. The drug is in phase III trials worldwide, and is licensed in Japan as an orphan drug for treatment of Castleman's disease.

In a phase II European trial of toclizumab, 61% of patients had an ACR20 response, 43% had an ACR50 response, and 16% had an ACR70 response at a dose of 8 mg/kg.